Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children

Journal of Medical Virology

Volumn 79, Issue 9, 2007, Pages 1261-1269

  Delaugerre, Constance ^a   Warszawski, Josiane ^b   Chaix, Marie Laure ^a   Veber, Florence ^a   Macassa, Eugenia ^a   Buseyne, Florence ^c   Rouzioux, Christine ^c   Blanche, Stéphane ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

Adherence; Children; Gender; HIV; Resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; FEMALE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TREATMENT FAILURE; VIRUS LOAD; VIRUS TYPING;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; FRANCE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; MALE; MUTATION; PREVALENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34547118092     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20940     Document Type: Article

References (28)

1. Aboulker JP, Babiker A, Chaix ML, Compagnucci A, Darbyshire J, Debre M, Faye A, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS. 2004. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 18:237-245.
2. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. 2003. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17:2159-2168.
3. Brindeiro PA, Brindeiro RM, Mortensen C, Hertogs K, De Vroey V, Rubini NP, Sion FS, De Sa CA, Machado DM, Succi RC, Tanuri A. 2002. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol 40:4512-4519.
4. Delaugerre C, Teglas JP, Treluyer JM, Vaz P, Jullien V, Veber F, Rouzioux C, Chaix ML, Blanche S. 2004. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr 37:1269-1275.
5. Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P. 2001. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis 183:1732-1738.
6. Faye A, Bertone C, Teglas JP, Chaix ML, Douard D, Firtion G, Thuret I, Dollfus C, Monpoux F, Floch C, Nicolas J, Vilmer E, Rouzioux C, Mayaux MJ, Blanche S. 2002. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J 21:518-525.
7. Felsenstein J. 2001. PHYLIP, Phylogeny Inference Package, version 3.6 (alpha). Seattle: Departement of genetics, UoW.
8. Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. 2004. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 189:1176-1184.
9. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37:113-128.
10. Johann-Liang R, Lee SE, Fernandez A, Cervia J, Noel GJ. 2000. Genotypic characterization of human immunodeficiency virus type 1 isolated from vertically infected children with antiretroviral therapy experience. Pediatr Infect Dis J 19:363-364.
11. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, Fiscus SA. 2001. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 183:1688-1693.
12. Jullien V, Urien S, Hirt D, Delaugerre C, Rey E, Teglas JP, Vaz P, Rouzioux C, Chaix ML, Macassa E, Firtion G, Pons G, Blanche S, Treluyer JM. 2006. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother 50:3548-3555.
13. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E. 2004. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 189:51-60.
14. Machado ES, Lambert JS, Watson DC, Afonso AO, da Cunha SM, Nogueira SA, Caride E, Oliveira RH, Sill AM, DeVico A, Tanuri A. 2004. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy. J Clin Virol 30:24-31.
15. MacManus , Yates PJ, Elston RC, White S, Richards N, Snowden W. 2004. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: Absence of protease resistance at 48 weeks. AIDS 18:651-655.
16. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait Mohand H, Cacace R, Bonmarchand M, Wirden M, Simon A, Bossi P, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V. 2003. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 47:594-600.
17. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. 2004. The role of psychosocial and family factors in adherence to antiretroviral treatment in human immunodeficiency virus-infected children. Pediatr Infect Dis J 23:1035-1041.
18. Mullen J, Leech S, O'Shea S, Chrystie IL, Du Mont G, Ball C, Sharland M, Cottam F, Zuckerman M, Rice P, Easterbrook P. 2002. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol 68:299-304.
19. Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR. 2005. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 159:764-770.
20. Regazzi M, Villani P, Seminari E, Ravasi G, Cusato M, Marubbi F, Meneghetti G, Maserati R. 2003. Sex differences in nevirapine disposition in HIV-infected patients. AIDS 17:2399-2400.
21. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, Bozzette SA. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401.
22. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dube MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, DAquila RT, Vella S, Merigan TC, Hirsch MS. 2003. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349:2293-2303.
23. Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG. 2004. The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 35:22-32.
24. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, Rich K, Handelsman E, Diaz C, Pagano M, Smeriglio V, Kalish LA. 1997. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 336:1337-1342.
25. Simonetti SR, Schatzmayr HG, Simonetti JP. 2003. Human immunodeficiency virus type 1: Drug resistance in treated and untreated Brazilian children. Mem Inst Oswaldo Cruz 98:831-837.
26. Study EC. 2002. Level and pattern of HIV-1-RNA viral load aver age: Differences between girls and boys? AIDS 16:97-104.
27. Tamalet C, Fantini J, Tourres C, Yahi N. 2003. Resistance of HIV-1 to multiple antiretroviral drugs in France: A 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 17:2383-2388.
28. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. 2004. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292:251-265.